Trauma Implant Market Size and Share
Market Definition
Implants and instruments such as plates, screws, intramedullary nails, pins, wires, staples and external fixators.
April 2026
Mike Evers, Senior Market Analyst
Welcome to our overview of the trauma market. This page builds upon and updates our trauma chapter in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT®.
For the second consecutive year, core trauma exceeded expectations, while procedure volume softness impacted the foot and ankle segment. All told, the trauma market grew in the mid-single digits. Trauma’s $9.6 billion in sales accounted for 15% of the nearly $65 billion global orthopedic market.
Market Forecast
Amid an extended downturn of the fast-growing foot and ankle segment, core trauma once again outperformed its historical average, driving the overall trauma market to mid-single digit growth. We expect those two factors to normalize over the coming years but to continue driving mid-single digit growth through 2029.
Exhibit 1: Worldwide Trauma Sales by Year ($million)
Get More Orthopedic Market Data. Download the Orthopedic Companies Sales Matrix for our most complete and granular numbers. It contains worldwide orthopedic sales for 80 public and private companies by segment from 2016 through 2025.
Here are some of the trauma market dynamics we considered in our forecast:
Demographic Tailwinds. The trauma segment benefits from a longer life expectancy and increased incidence of diabetes and obesity among potential patients. This patient population has compromised bone quality and structural integrity. According to the U.S. Department of Health and Human Services, just under a quarter of the population will be 65 or older by 2040. According to the Centers for Disease Control and Prevention (CDC), the prevalence of diagnosed diabetes in the U.S. population is about 9%. Likewise, 2023 data from the CDC showed a staggering 73% of the U.S. adult population was overweight or obese.
Foot and Ankle Volumes Down. While foot and ankle enjoys a high-single digit growth rate, surgical volumes have traditionally been choppy. The number of procedures slowed in late 2023 and remained inconsistent throughout much of 2024. Most of the top companies in trauma said 2025 was slow as well. How much longer could the soft market last? There were signs of life in the second half of 2025, and Stryker, for one, thinks 2026 will bring a better market environment.
Digital Solutions on the Horizon. We expect more trauma-focused enabling technologies to hit the market in the coming years. Eric Tamweber, Stryker’s Vice President and General Manager of Trauma, identified enabling technology as the biggest growth opportunity in core trauma. DePuy Synthes teased its VELYS Trauma AI-Assisted Surgery system at AAOS in early 2026. How much value can technology bring to trauma care? We’ve seen its impact on revenue and growth in joint replacement and, to a lesser extent, spine. However, the complexity and variability of fractures pose a difficult problem to solve.
More Market Overviews
Sales by Region
While the United States is the largest trauma market, it is highly consolidated and can be difficult to penetrate without a novel, differentiated offering. However, international markets were an area of strength for many trauma players in 2025.
Europe’s robust demand has made it a growth engine for companies that have secured certification for their products under the European Union Medical Device Regulation (MDR). European companies have generated substantial growth in EMEA region. Medartis’s EMEA sales, for instance, have an estimated CAGR of 11% from 2019 to 2025.
While companies have lapped the impact of volume-based procurement (VBP) price cuts in China, that market remains very much in flux. VBP’s volume benefit has largely gone to domestic Chinese companies. International players are often deciding to stay in or leave the market on a product-by-product basis, as the new paradigm is hard to make profitable.
As in Europe and the Asia Pacific region, it is hard to generalize about the orthopedic markets in the countries that make up Latin America. We recently spoke with leadership of the Americas for Citieffe, an orthopedic trauma company based in Italy. They said organic growth is low in Latin America, more competitors from Asia are entering the market, and the regulatory approval process for new technologies is lengthy. These factors, along with relatively little investment in healthcare, make for a very fragmented orthopedic market.
Exhibit 2: Trauma Sales by Region ($million)
| Region | 2025 | 2024 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $6,314.3 | $5,986.3 | $328.0 | 5.5% |
| OUS | $3,281.9 | $3,083.8 | $198.1 | 6.4% |
| EMEA | $1,765.7 | $1,659.8 | $105.9 | 6.4% |
| APAC | $1,055.6 | $997.7 | $57.9 | 5.8% |
| ROW | $460.6 | $426.3 | $34.3 | 8.1% |
| Total | $9,596.2 | $9,070.1 | $526.1 | 5.8% |
Exhibit 3: Trauma Market Share by Region ($million)
Top Companies
Trauma is an extremely consolidated market. Stryker and J&J MedTech are the top two players, accounting for 60% of the segment’s global sales.
Johnson & Johnson MedTech’s trauma business is more than three times larger than the next largest player, Zimmer Biomet, which benefited from the early-2025 acquisition of Paragon 28. Smith+Nephew and Acumed round up the market’s top five players, who account for a combined 80% of the market.
Exhibit 4: Top 10 Trauma Players and All Others ($million)
| Company | 2025 | 2024 | $ Chg | % Chg |
|---|---|---|---|---|
| Stryker | $2,957.8 | $2,625.9 | $331.9 | 12.6% |
| J&J MedTech | $2,791.5 | $2,713.1 | $78.4 | 2.9% |
| Zimmer Biomet | $869.8 | $663.5 | $206.3 | 31.1% |
| Smith+Nephew | $564.3 | $530.4 | $33.8 | 6.4% |
| Acumed | $436.7 | $418.9 | $17.8 | 4.3% |
| Medartis | $268.4 | $238.0 | $30.4 | 12.8% |
| Arthrex | $247.0 | $235.0 | $12.0 | 5.1% |
| Treace Medical Concepts | $212.7 | $209.4 | $3.3 | 1.6% |
| Orthofix | $134.7 | $124.2 | $10.5 | 8.4% |
| OrthoPediatrics | $133.9 | $126.7 | $7.2 | 5.6% |
| All Others | $979.6 | $1,185.1 | ($205.5) | (21%) |
| Total | $9,596.2 | $9,070.1 | $526.1 | 5.8% |
As a reminder, we use as-reported sales figures, which had a meaningful impact on trauma in 2025 because of Zimmer Biomet’s acquisition of Paragon 28. The transaction closed at the start of the second quarter. On a pro forma basis, Zimmer Biomet’s trauma growth was 0.9%. As reported, however, those Paragon 28 revenues are logged in the 2024 All Others line, which explains the apparent large decline.
Exhibit 5: Trauma Market Share by Company ($million)
Like other players in the foot and ankle market, Stryker had a softer year for sales. However, the company’s success in core trauma more than offset the slowdown in foot and ankle. The Pangea Plating System not only drove sales growth but also increased customer awareness of Stryker’s broad trauma offering.
Johnson & Johnson’s spin-off of DePuy Synthes could create some disruption in 2026 and 2027, but it was mostly business as usual last year. The company’s trauma product growth improved each quarter, with the second half of the yearperforming far stronger than the first. International sales and the VOLT Plating System were key growth drivers.
Among mid-tier companies, Zimmer Biomet worked through its Paragon 28 integration during 2025. The company had to address “contract friction” but remains bullish on the long-term growth prospects for the business. Smith+Nephew saw good growth from the EVOS plating system, which was partially offset by slower sales of legacy systems. In late 2025, Acumed announced completion of the first wrist fixation case using Acu-Loc NEXT, an update of the original Acu-Loc system..
Among smaller players, Treace Medical endured a rocky 2025 as it navigated evolving preferences among patients and surgeons and the broader slowdown in the foot and ankle market. Orthofix found success penetrating the U.S. market with its complex limb reconstruction portfolio, while Enovis and Globus Medical saw their trauma businesses begin to reach critical mass.
Important Developments in the Trauma Market
Potential Disruption on the Way. J&J MedTech plans to separate its orthopedics business to operate as DePuy Synthes by 2027 and said things would be “business as usual” until then. Trauma is one of J&J MedTech’s best performing segments; however, it is ahistorical to think a company can make changes of this magnitude without experiencing disruption. The spin-off will likely affect DePuy Synthes’ sales and create opportunity for other companies to take market share.
Mid-tier Players Build a Base. Globus Medical and Enovis are among the largest players in orthopedics but until recently had very little representation in the trauma market. According to our estimates, both companies surpassed $100 million in trauma sales in 2025. Globus Medical’s legacy trauma offering is about 80% complete and benefitted from the addition of NuVasive’s NSO products. Enovis’ experienced slowing foot and ankle volumes last year but noted signs of a rebound starting in the third quarter. Large and medium-sized orthopedic companies are seeing success as they expand their presence in the trauma market. Arthrex and Orthofix are additional examples. We expect companies to continue to focus on trauma portfolio opportunities that are synergetic with their other offerings.
Bunion Market Changing Quickly. Numerous companies have entered the bunion market in recent years, creating a competitive, rapidly evolving environment. Treace Medical spent 2025 expanding its portfolio to compete for 100% of bunion cases. While the move helped expand case volumes, Treace experienced pressure on its Lapiplasty procedures as surgeons and patients shifted toward minimally invasive osteotomies. Additionally, the company’s survey of its surgeons indicated a 7% volume decline year-over-year as patients deferred elective procedures, especially those with commercial insurance.
Rise in Non-Metal Implants. Bio-integrative and absorbable implants are experiencing greater market adoption. Companies like OSSIO and Bioretec have improved the weight-bearing strength and degradation process of their implant materials, creating opportunities for patients’ fractures to heal without the need for long-term metal implants. Advancements in this technology could be meaningful for pediatric and young adult patients, who often undergo a second surgery to have their metal screws removed after their fractures heal.
Filling Gaps in Niche Indications. Smaller companies are entering the market with novel technologies that address the needs of patients undergoing more complex procedures or those with high revision rates. Specifically, pelvis and hip fractures are on the rise as the population ages, and these patients could benefit from improved implant offerings. CurvaFix recently received FDA clearance for its Low Profile System, a percutaneous solution for the fixation of pelvic fractures. Hyprevention received Breakthrough Device Designation for its Y-STRUT Hip Implant for patients with cancer presenting with bone metastasis or lesions in the proximal femur.
Small Company Portfolio Expansion. Niche technologies aside, smaller players in the trauma market often specialize in lower extremity or upper extremity products. As large orthopedic companies turn their attention to the trauma market and have the infrastructure to scale, it could be difficult for smaller, focused companies to compete for large hospital and ASC contracts. This is also true for U.S. companies with international aspirations. Most OUS players in the trauma market have deep trauma portfolios. Companies that seek to build rather than be acquired are expected to expand their product pipeline to gain additional market share.
Further Reading
Thanks for visiting! Need more insight on the trauma market? Questions and comments are always welcome. You can reach me by email. Until then, I’ve selected a few posts that give insight into our thinking on the trauma market.
Our overview of the trauma market includes up-to-date information on forecasted growth, the top companies and industry-driving trends.
Market Definition
Implants and instruments such as plates, screws, intramedullary nails, pins, wires, staples and external fixators.
April 2026
Mike Evers, Senior Market Analyst
Welcome to our overview of the trauma market. This page builds upon and updates our trauma chapter in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT®.
For the second consecutive year, core trauma exceeded expectations, while procedure volume softness impacted the foot and ankle segment. All told, the trauma market grew in the mid-single digits. Trauma’s $9.6 billion in sales accounted for 15% of the nearly $65 billion global orthopedic market.
Market Forecast
Amid an extended downturn of the fast-growing foot and ankle segment, core trauma once again outperformed its historical average, driving the overall trauma market to mid-single digit growth. We expect those two factors to normalize over the coming years but to continue driving mid-single digit growth through 2029.
Exhibit 1: Worldwide Trauma Sales by Year ($million)
Get More Orthopedic Market Data. Download the Orthopedic Companies Sales Matrix for our most complete and granular numbers. It contains worldwide orthopedic sales for 80 public and private companies by segment from 2016 through 2025.
Here are some of the trauma market dynamics we considered in our forecast:
Demographic Tailwinds. The trauma segment benefits from a longer life expectancy and increased incidence of diabetes and obesity among potential patients. This patient population has compromised bone quality and structural integrity. According to the U.S. Department of Health and Human Services, just under a quarter of the population will be 65 or older by 2040. According to the Centers for Disease Control and Prevention (CDC), the prevalence of diagnosed diabetes in the U.S. population is about 9%. Likewise, 2023 data from the CDC showed a staggering 73% of the U.S. adult population was overweight or obese.
Foot and Ankle Volumes Down. While foot and ankle enjoys a high-single digit growth rate, surgical volumes have traditionally been choppy. The number of procedures slowed in late 2023 and remained inconsistent throughout much of 2024. Most of the top companies in trauma said 2025 was slow as well. How much longer could the soft market last? There were signs of life in the second half of 2025, and Stryker, for one, thinks 2026 will bring a better market environment.
Digital Solutions on the Horizon. We expect more trauma-focused enabling technologies to hit the market in the coming years. Eric Tamweber, Stryker’s Vice President and General Manager of Trauma, identified enabling technology as the biggest growth opportunity in core trauma. DePuy Synthes teased its VELYS Trauma AI-Assisted Surgery system at AAOS in early 2026. How much value can technology bring to trauma care? We’ve seen its impact on revenue and growth in joint replacement and, to a lesser extent, spine. However, the complexity and variability of fractures pose a difficult problem to solve.
More Market Overviews
Sales by Region
While the United States is the largest trauma market, it is highly consolidated and can be difficult to penetrate without a novel, differentiated offering. However, international markets were an area of strength for many trauma players in 2025.
Europe’s robust demand has made it a growth engine for companies that have secured certification for their products under the European Union Medical Device Regulation (MDR). European companies have generated substantial growth in EMEA region. Medartis’s EMEA sales, for instance, have an estimated CAGR of 11% from 2019 to 2025.
While companies have lapped the impact of volume-based procurement (VBP) price cuts in China, that market remains very much in flux. VBP’s volume benefit has largely gone to domestic Chinese companies. International players are often deciding to stay in or leave the market on a product-by-product basis, as the new paradigm is hard to make profitable.
As in Europe and the Asia Pacific region, it is hard to generalize about the orthopedic markets in the countries that make up Latin America. We recently spoke with leadership of the Americas for Citieffe, an orthopedic trauma company based in Italy. They said organic growth is low in Latin America, more competitors from Asia are entering the market, and the regulatory approval process for new technologies is lengthy. These factors, along with relatively little investment in healthcare, make for a very fragmented orthopedic market.
Exhibit 2: Trauma Sales by Region ($million)
| Region | 2025 | 2024 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $6,314.3 | $5,986.3 | $328.0 | 5.5% |
| OUS | $3,281.9 | $3,083.8 | $198.1 | 6.4% |
| EMEA | $1,765.7 | $1,659.8 | $105.9 | 6.4% |
| APAC | $1,055.6 | $997.7 | $57.9 | 5.8% |
| ROW | $460.6 | $426.3 | $34.3 | 8.1% |
| Total | $9,596.2 | $9,070.1 | $526.1 | 5.8% |
Exhibit 3: Trauma Market Share by Region ($million)
Top Companies
Trauma is an extremely consolidated market. Stryker and J&J MedTech are the top two players, accounting for 60% of the segment’s global sales.
Johnson & Johnson MedTech’s trauma business is more than three times larger than the next largest player, Zimmer Biomet, which benefited from the early-2025 acquisition of Paragon 28. Smith+Nephew and Acumed round up the market’s top five players, who account for a combined 80% of the market.
Exhibit 4: Top 10 Trauma Players and All Others ($million)
| Company | 2025 | 2024 | $ Chg | % Chg |
|---|---|---|---|---|
| Stryker | $2,957.8 | $2,625.9 | $331.9 | 12.6% |
| J&J MedTech | $2,791.5 | $2,713.1 | $78.4 | 2.9% |
| Zimmer Biomet | $869.8 | $663.5 | $206.3 | 31.1% |
| Smith+Nephew | $564.3 | $530.4 | $33.8 | 6.4% |
| Acumed | $436.7 | $418.9 | $17.8 | 4.3% |
| Medartis | $268.4 | $238.0 | $30.4 | 12.8% |
| Arthrex | $247.0 | $235.0 | $12.0 | 5.1% |
| Treace Medical Concepts | $212.7 | $209.4 | $3.3 | 1.6% |
| Orthofix | $134.7 | $124.2 | $10.5 | 8.4% |
| OrthoPediatrics | $133.9 | $126.7 | $7.2 | 5.6% |
| All Others | $979.6 | $1,185.1 | ($205.5) | (21%) |
| Total | $9,596.2 | $9,070.1 | $526.1 | 5.8% |
As a reminder, we use as-reported sales figures, which had a meaningful impact on trauma in 2025 because of Zimmer Biomet’s acquisition of Paragon 28. The transaction closed at the start of the second quarter. On a pro forma basis, Zimmer Biomet’s trauma growth was 0.9%. As reported, however, those Paragon 28 revenues are logged in the 2024 All Others line, which explains the apparent large decline.
Exhibit 5: Trauma Market Share by Company ($million)
Like other players in the foot and ankle market, Stryker had a softer year for sales. However, the company’s success in core trauma more than offset the slowdown in foot and ankle. The Pangea Plating System not only drove sales growth but also increased customer awareness of Stryker’s broad trauma offering.
Johnson & Johnson’s spin-off of DePuy Synthes could create some disruption in 2026 and 2027, but it was mostly business as usual last year. The company’s trauma product growth improved each quarter, with the second half of the yearperforming far stronger than the first. International sales and the VOLT Plating System were key growth drivers.
Among mid-tier companies, Zimmer Biomet worked through its Paragon 28 integration during 2025. The company had to address “contract friction” but remains bullish on the long-term growth prospects for the business. Smith+Nephew saw good growth from the EVOS plating system, which was partially offset by slower sales of legacy systems. In late 2025, Acumed announced completion of the first wrist fixation case using Acu-Loc NEXT, an update of the original Acu-Loc system..
Among smaller players, Treace Medical endured a rocky 2025 as it navigated evolving preferences among patients and surgeons and the broader slowdown in the foot and ankle market. Orthofix found success penetrating the U.S. market with its complex limb reconstruction portfolio, while Enovis and Globus Medical saw their trauma businesses begin to reach critical mass.
Important Developments in the Trauma Market
Potential Disruption on the Way. J&J MedTech plans to separate its orthopedics business to operate as DePuy Synthes by 2027 and said things would be “business as usual” until then. Trauma is one of J&J MedTech’s best performing segments; however, it is ahistorical to think a company can make changes of this magnitude without experiencing disruption. The spin-off will likely affect DePuy Synthes’ sales and create opportunity for other companies to take market share.
Mid-tier Players Build a Base. Globus Medical and Enovis are among the largest players in orthopedics but until recently had very little representation in the trauma market. According to our estimates, both companies surpassed $100 million in trauma sales in 2025. Globus Medical’s legacy trauma offering is about 80% complete and benefitted from the addition of NuVasive’s NSO products. Enovis’ experienced slowing foot and ankle volumes last year but noted signs of a rebound starting in the third quarter. Large and medium-sized orthopedic companies are seeing success as they expand their presence in the trauma market. Arthrex and Orthofix are additional examples. We expect companies to continue to focus on trauma portfolio opportunities that are synergetic with their other offerings.
Bunion Market Changing Quickly. Numerous companies have entered the bunion market in recent years, creating a competitive, rapidly evolving environment. Treace Medical spent 2025 expanding its portfolio to compete for 100% of bunion cases. While the move helped expand case volumes, Treace experienced pressure on its Lapiplasty procedures as surgeons and patients shifted toward minimally invasive osteotomies. Additionally, the company’s survey of its surgeons indicated a 7% volume decline year-over-year as patients deferred elective procedures, especially those with commercial insurance.
Rise in Non-Metal Implants. Bio-integrative and absorbable implants are experiencing greater market adoption. Companies like OSSIO and Bioretec have improved the weight-bearing strength and degradation process of their implant materials, creating opportunities for patients’ fractures to heal without the need for long-term metal implants. Advancements in this technology could be meaningful for pediatric and young adult patients, who often undergo a second surgery to have their metal screws removed after their fractures heal.
Filling Gaps in Niche Indications. Smaller companies are entering the market with novel technologies that address the needs of patients undergoing more complex procedures or those with high revision rates. Specifically, pelvis and hip fractures are on the rise as the population ages, and these patients could benefit from improved implant offerings. CurvaFix recently received FDA clearance for its Low Profile System, a percutaneous solution for the fixation of pelvic fractures. Hyprevention received Breakthrough Device Designation for its Y-STRUT Hip Implant for patients with cancer presenting with bone metastasis or lesions in the proximal femur.
Small Company Portfolio Expansion. Niche technologies aside, smaller players in the trauma market often specialize in lower extremity or upper extremity products. As large orthopedic companies turn their attention to the trauma market and have the infrastructure to scale, it could be difficult for smaller, focused companies to compete for large hospital and ASC contracts. This is also true for U.S. companies with international aspirations. Most OUS players in the trauma market have deep trauma portfolios. Companies that seek to build rather than be acquired are expected to expand their product pipeline to gain additional market share.
Further Reading
Thanks for visiting! Need more insight on the trauma market? Questions and comments are always welcome. You can reach me by email. Until then, I’ve selected a few posts that give insight into our thinking on the trauma market.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
